Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC is critically appraising the company’s submission to NICE on a new drug for chronic hepatitis C

Published: 5 January 2015

SHTAC is assessing the clinical-effectiveness and cost-effectiveness of ombitasvir/paritaprevir/ritonavir with or without dasabuvir in treating chronic hepatitis C as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal process.

Chronic hepatitis C is a liver disease caused by the blood-borne hepatitis C virus. The virus is transmitted between individuals through exposure to blood containing the virus. Around 80 to 85% of people who contract the virus do not naturally clear it and develop chronic hepatitis C. Some people with chronic hepatitis C do not experience any symptoms, while others can experience a range of symptoms including itch, fatigue and depression. Chronic hepatitis C is a progressive condition and around 30% of people who have it will eventually develop cirrhosis of the liver, which may require liver transplantation in some people. A minority of people with cirrhosis may develop the complication of hepatocellular carcinoma.

Ombitasvir/paritaprevir/ritonavir is among a number of new drugs that have recently been developed for the treatment of chronic hepatitis C. It is administered orally with or without oral dasabuvir to inhibit viral replication.

SHTAC will be critically appraising the company’s evidence submission to NICE on the clinical and cost effectiveness of the co-formulated drug ombitasvir/paritaprevir/ritonavir with or without dasabuvir in treating chronic hepatitis C. NICE is expected to issue guidance to the NHS in September 2015.

For more information about SHTAC’s chronic hepatitis C research, please see our research page.

Privacy Settings